Contrast agents for applications including perfusion imaging

Patent metadata

Field	Value
Publication number	US-10245332-B2
Application number	US-201615153502-A
Country	US
Kind code	B2
Filing date	May 12, 2016
Priority date	Feb 29, 2008
Publication date	Apr 2, 2019
Grant date	Apr 2, 2019

Abstract

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the subject using diagnostic imaging.

First claim

What is claimed is:

1. A method of imaging cancer in a subject, comprising:
administering to a subject with cancer a contrast agent which comprises an imaging moiety and a compound bound to the imaging moiety, scanning the patient using diagnostic imaging to produce an image of at least a portion of the cancer, wherein the contrast agent has a structure as in Formula (II),

wherein:
J is selected from N(R 27 ) S, O, C(═O), C(═O)O, NHCH 2 CH 2 O, a bond, or C(═O)N(R 27 );
K and L, when present, are independently selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl, heteroaryl, and an imaging moiety, each of which is optionally substituted;
M is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl, heteroaryl, and an imaging moiety, each of which is optionally substituted, or
L and M, together with the atom to which they are attached, form a ring, optionally substituted;
Q is halo or haloalkyl;
n is 0, 1, 2, or 3;
R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 are independently selected from hydrogen, alkyl,
optionally substituted, and an imaging moiety;
R 29 is alkyl, optionally substituted; and
Y is selected from a bond, carbon, and oxygen; provided that when Y is a bond, K and L are
absent and M is selected from aryl and heteroaryl, each of which is optionally substituted; and
provided that when Y is oxygen, K and L are absent and M is selected from hydrogen, alkoxyalkyl,
aryl, alkyl, and heteroaryl, each of which is optionally substituted,
wherein at least one imaging moiety is present in Formula (II) and is 18 F.

2. The method as in claim 1 , wherein the image is used in the diagnosis of a subject.

3. The method as in claim 2 , wherein the diagnosis is a diagnosis of a cancer.

4. The method as in claim 1 , wherein the image is used to determine the stage of a cancer.

5. The method as in claim 1 , further comprising selecting a treatment of a cancer in the subject based at least in part on the image of at least a portion of the cancer.

6. The method as in claim 1 , further comprising evaluating a treatment of a cancer in the subject based at least in part on the image of at least a portion of the cancer.

7. The method as in claim 1 , wherein the cancer is a primary tumor or neoplasia.

8. The method as in claim 1 , wherein the cancer is a metastatic growth.

9. The method as in claim 1 , wherein J is O and R 29 is C 1 -C 6 alkyl.

10. The method as in claim 1 , wherein R 29 is tert-butyl.

11. The method as in claim 1 , wherein M is alkoxyalkyl, optionally substituted with an imaging moiety.

12. The method as in claim 1 , wherein the contrast agent is selected from the following group:

13. The method as in claim 1 , wherein the contrast agent is:

14. The method as in claim 2 , wherein the contrast agent is:

15. The method as in claim 3 , wherein the contrast agent is:

16. The method as in claim 4 , wherein the contrast agent is:

17. The method as in claim 5 , wherein the contrast agent is:

18. The method as in claim 6 , wherein the contrast agent is:

19. The method as in claim 7 , wherein the contrast agent is:

20. The method as in claim 8 , wherein the contrast agent is:

Assignees

• Lantheus Medical Imaging Inc

Inventors

• Robinson Simon P
• Casebier David S
• Yu Ming
• Kagan Mikhail
• Lazewatsky Joel

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K51/0459 Primary

  having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine · CPC title